BIOSTAGE, INC. (NASDAQ:BSTG) Files An 8-K Entry into a Material Definitive Agreement
On December 31, 2019, Biostage, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with an individual investor as described in the SPA (the “Investor”) to which the Investor agreed to purchase in a private placement 81,081 shares of common stock and warrants to purchase 81,081 shares of common stock (the “Investor Warrant”) for the aggregate purchase price of approximately $300,000 and a purchase price per share and warrant of $3.70 (the “Private Placement”). The Private Placement closed on December 31, 2019.
The Investor Warrant has an exercise price of $3.70 per share, subject to adjustments as provided under the terms thereof, and is immediately exercisable. The Investor Warrant is exercisable until April 30, 2020. The SPA and Investor Warrant each include customary representations, warranties and covenants.
As described below in Item 3.02, the Company has also issued additional shares in private placements with a number of other investors, which including the $300,000 provided by the Investor, resulted in funding of approximately $718,000 in the aggregate to the Company.
The representations, warranties and covenants contained in the SPA were made solely for the benefit of the parties to the SPA. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the SPA and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the SPA is included with this filing only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the SPA, which subsequent information may or may not be fully reflected in public disclosures.
The SPA and the form of Investor Warrant are filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.
The information contained above in Item 1.01 related to the Private Placement is hereby incorporated by reference into this Item 3.02. In addition to the Private Placement, on December 31, 2019, the Company also issued additional shares in private placements with a number of other investors, which including the $300,000 provided by the Investor as described in Item 1.01 above, resulted in funding of approximately $718,000 in the aggregate to the Company.
Such private placements were comprised of:
(i) an aggregate of 143,230 shares of common stock and warrants to purchase 143,230 shares of common stock a purchase price per share and warrant of $3.70, resulting in proceeds of approximately $530,000 to the Company. Such figures include the Private Placement described above, and in such placements the other investors each executed a securities purchase agreement similar to the Investor SPA and received a warrant similar to the Investor Warrant; and
(ii) an aggregate of 94,000 shares issued in connection with investors who exercised warrants issued by the Company in December 2017 which the investors had acquired via assignment by DST Capital LLC. In connection with such exercise, the Company received proceeds of approximately $188,000.
The shares of common stock and the warrants issued to the Investor and the other investors described above (as well as any shares issuable upon exercise of the Investor Warrant and other warrants described above), were and will be sold and issued without registration under the Securities Act in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to an accredited investor, and in reliance on similar exemptions under applicable state laws.
On January 2, 2020, the Company issued a press release providing an update on the U.S. Food and Drug Administration’s review of the company’s Investigational New Drug application for its CellspanTM Esophageal Implant (CEI) for treatment of esophageal conditions, and other matters. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 8.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|4.1||Form of Common Stock Purchase Warrant.|
|10.1||Securities Purchase Agreement dated as of December 31, 2019.|
|99.1||Press Release issued on January 2, 2020.|
Biostage, Inc. Exhibit
EX-4.1 2 tm201082d1_ex4-1.htm EXHIBIT 4.1 EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933,…
To view the full exhibit click
About BIOSTAGE, INC. (NASDAQ:BSTG)
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.